From “insulin stimulants” to “drugs that restore early-phase insulin secretion and improve pancreatic B-cell function while lowering glucose”, it is currently believed that the main causes of type 2 diabetes are insufficient early-phase insulin secretion and insulin resistance. In addition, insulin resistance is also the source of various metabolic abnormalities such as dyslipidemia, hypertension, hypercoagulability, abdominal obesity, and chronic complications such as cardiovascular disease. Therefore, the treatment of type 2 diabetes must start at the source, improve the function of pancreatic B cells, reduce insulin resistance, thereby achieving control of hyperglycemia and other risk factors, delaying the progression of type 2 diabetes and reducing the occurrence and development of chronic complications of diabetes. An analysis of combination treatment regimens for type 2 diabetes in China showed that insulinotropic agents + metformin was the most commonly used clinical combination regimen of oral hypoglycemic agents (about 27%). Since insufficient insulin secretion by pancreatic islet cells is an important pathophysiological change in type 2 diabetes, and the potent glucose-lowering ability of glucagon is a strong guarantee for achieving the blood glucose target, and long-term intensive glucose-lowering therapy based on glucagon has been proved to reduce vascular complications. Therefore, pro-secretory agents are an important option for the treatment of type 2 diabetes. For patients with type 2 diabetes, the loss of early-phase insulin secretion usually results in postprandial hyperglycemia and even causes a series of metabolic disorders, so the application of early-phase insulin stimulants (such as Repaglinide and Neglinide) is of more concern. However, inappropriate use of insulin sensitizers (such as euglycemia) not only fails to protect pancreatic B cells, but also accelerates the failure of pancreatic B cells and leads to secondary failure of hypoglycemic drugs. In contrast, insulin sensitizers (e.g. thiazolidinediones) both lower glucose and improve islet B-cell function. What is more noteworthy: the new glucose-lowering drug enteroglucagon, glucagon-like peptide 1 (GLP-1), a new glucose-lowering drug with a new glucose-lowering mechanism such as exenatide and liraglutide, etc. This drug can bring many benefits to patients as follows: ①GLP-1 can stimulate insulin secretion and inhibit glucagon secretion, and these effects (2) GLP-1 can improve B-cell function; (3) GLP-1 delays gastric emptying, improves postprandial glucose control, and reduces appetite, which helps to reduce body weight. There are also new drugs dipeptidyl peptidase-4 (DPP-4) inhibitors (such as sitagliptin, vincristine, saxagliptin). The DPP-4 inhibitors (such as selegiline 100mg) can increase the postprandial GLP-1 level by more than 1 to 2 times after oral administration, and the GLP-1 level in the morning after taking the drug is still significantly higher. 1 levels remained elevated more significantly the next morning after taking the drug, suggesting that selegiline not only elevates postprandial GLP-1 concentrations but also increases basal levels of GLP-1. Strictly speaking the efficacy of DPP-4 inhibitors is achieved by increasing glucagon-like peptide 1 (GLP-1) in the body, so to say: DPP-4 inhibitors are equally capable of multiple glucose lowering without weight gain or weight loss. It brings a whole new opportunity for the treatment of type 2 diabetes. It not only helps to achieve long-term stable glycemic control and delay the progression of type 2 diabetes, but also reduces the incidence of diabetic microvascular and macrovascular disease. From “monitoring blood glucose” to “comprehensive diabetes management”, comprehensive diabetes management means that we should not only manage blood glucose, but also blood pressure, blood lipids, weight, blood uric acid, etc. The steno2 study at the Danish Diabetes Center is the best evidence of the benefits of comprehensive management of diabetes: the beneficial effects of the comprehensive diabetes management group, i.e., the multiple risk factor intervention group, on microvascular complications were found after 3.8 years of observation; the beneficial effects of the multiple risk factor intervention group on macrovascular complications were found after 7.8 years of observation; and after 5 years of follow-up, the beneficial effects of the comprehensive diabetes management group on macrovascular complications were found even though blood glucose, lipids, and blood pressure were similarly controlled. At a further 5 years of follow-up, it was found that even if glycemic, lipid and blood pressure control were similar, the total diabetes management group still reduced macrovascular complications and all-cause mortality in diabetic patients. Such a study gives us a very important insight that diabetes needs to be managed in a comprehensive manner to achieve the goals. So how to perform comprehensive management of diabetic patients? By building a clinical treatment center with the integration of information, education, treatment and follow-up, Liu Peiwen’s studio at Xinhua Hospital in Hubei Province not only cares about the glucose, blood pressure and lipids of diabetics, but also their quality of life, so that patients can enjoy a full range of caring services and create a “warm” environment for patients. We have created a “warm home” for our patients. We believe that the new concept of diabetes treatment can bring a new dawn for diabetic patients and make their life better.